A Pilot Study on Reverse Aging (The REVERSE Study)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 52
研究概览
简要总结
Aging can be defined as a time-dependent functional decline in physiological function, which may increase the vulnerability to diseases and eventually death. The question is whether aging is a normal process, or exists as an "uber-illness?" Work done by Dr Sinclair at Harvard suggests the latter. Dr. Sinclair feels people should be able to age-in-place, or even reverse age. Aging is arguably the single biggest risk factor for all acquired and chronic diseases. Delaying the aging rate by 7 years would cut the incidence of chronic disease in half! Up until know the effects of anti-aging would need longitudinal studies until death.
Now, with the advent of a 3rd generation OMIC Age clock, there is a way to assess if an intervention is changing the rate of aging and other methylation patterns associated with aging.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be healthy and of any sex, any ethnicity, and any age from 50 to 80
- •"Healthy" subjects will be defined as a real-world cohort of individuals likely to utilize such an intervention
- •May be on other medications if they do not conflict with rapamycin.
- •All medical conditions need to be stable and well controlled.
- •Willing and able to provide informed consent
排除标准
- •Severe illnesses, for which rapamycin may cause harm. This would not be limited to but include active neoplastic or auto-immune disease. If patients have a previous history of cancer or auto-immune disease, the risks and benefits and possible adverse reactions will be discussed at time of consent
- •History of organ transplant
- •Any unstable medical condition that would interfere with the study
- •Hepatic impairment. Note: Patients with elevated liver enzymes and low albumin, will be further screened for hepatic impairment. Elevated liver enzymes < 2x upper limit of normal will not be considered hepatic impairment.
- •Renal impairment, indicated by a serum creatinine > 1.4 mg/dL
- •Anemia indicated by a hemoglobin < 12 g/dL
- •Platelets < 80,000/cumm,
- •ANC < 1,000 / cumm
- •Total WBC < 3,000/cumm
- •Pregnancy or breastfeeding or woman of childbearing potential with inadequate contraception
- •Unstable mental illness
- •A condition where rapamycin may interfere deleteriously with a medication that is taken by a potential subject
- •Currently prescribed with high dose CYP3A4 pathway medications such as verapamil > 240 mg; simvastatin >40 mg, lovastatin > 40 mg or atorvastatin > 40 mg daily. Poor GI motility as demonstrated by delayed gastric emptying on a radionucleotide isotope scan.
- •Intercurrent severe infection at initiation of study drug
- •Any and all other reasons that the investigator may determine that the participant is not suitable for study enrollment.
- •History of or active eating disorders as deemed by PI.
- •BMI lower than 18.5
- •Any medication that may dangerously lower glucose while on the FMD. This will include insulin, sulfonylureas (glyburide; glipizide); Thiazolidenediones ( eg piogltazone; rosiglitazone); GLP1 drugs (semaglutide; tirzepatide);; DPP-4 inhibitors (eg sitagliptin; saxagliptin); Alpha -glucosidase inhibitors (acarbose; miglitol). Patients on SGLT2 inhibitors (empagliflozin; canagliflozin) and Metformin (glucophage) may be included in the study.
研究者
Steve Amoils
Principal Investigator
The Christ Hospital